Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL3162158 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5821250 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665344 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665291 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7630144 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL12485521 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL973873 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 83997 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146232-A1 | METHODS FOR PROMOTING HOMING AND ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3978473-B1 | COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-0629697-A2 | Materials and methods for screening anti-osteoporosis agents | ELI LILLY AND COMPANY (US) | 1994-12-21 | — | — | EP | claimed |
| CN-1094042-A | Improvement about benzothiophene kind | LILLY CO ELI (US) | 1994-10-26 | — | — | CN | claimed |
| WO-1994023068-A1 | METHOD FOR SCREENING FOR RECEPTOR AGONISTS | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 1994-10-13 | — | — | WO | claimed |
| EP-0605193-A1 | Use of benzothiophenes for treatment of hypercholesterolaemia | ELI LILLY AND COMPANY (US) | 1994-07-06 | — | — | EP | claimed |
| CN-1088205-A | The improvement of thionaphthene and correlative thereof | LILLY CO ELI (US) | 1994-06-22 | — | — | CN | claimed |
| EP-0584952-A1 | Improvements in or relating to benzothiophenes | ELI LILLY AND COMPANY (US) | 1994-03-02 | — | — | EP | claimed |
| CN-1081682-A | Steroid derivatives | LILLY CO ELI (US) | 1994-02-09 | — | — | CN | claimed |
| EP-0562849-A2 | Steroid derivatives | ELI LILLY AND COMPANY (US) | 1993-09-29 | — | — | EP | claimed |
| US-4418068-A | Antiestrogenic and antiandrugenic benzothiophenes | ELI LILLY AND COMPANY (US) | 1983-11-29 | — | — | US | claimed |
| EP-0062503-A1 | Benzothiophene compounds and process for preparing them | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | claimed |